Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00484510 · ClinicalTrials.gov registry record · Phase 2
High Dose Ascorbic Acid Treatment of CMT1A
A Phase 2 study, sponsored by Wayne State University.
- Completed
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
NCT00484510: Completed Phase 2 study, sponsored by Wayne State University.
NCT00484510 is a Phase 2 study that has completed, run by Wayne State University. The registered enrollment target is 110 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00484510, a Phase 2 study, has completed, sponsored by Wayne State University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
Study Summary
This study will look at the impact of ascorbic acid (Vitamin C) on the progression of disease in people with CMT1A as compared to volunteers receiving a placebo. This study will assess whether is it futile to proceed with a larger, longer-term, placebo-controlled study.
Interventions
- DRUG placebo
- DRUG Ascorbic acid (Vitamin C)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2007-04 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
What the finished NCT00484510 record still lists
NCT00484510 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00484510 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00484510 about?
NCT00484510 is a clinical study titled "High Dose Ascorbic Acid Treatment of CMT1A". This study will look at the impact of ascorbic acid (Vitamin C) on the progression of disease in people with CMT1A as compared to volunteers receiving a placebo. This study will assess whether is it futile to proceed with a larger, longer-term, placebo-controlled study.
What is the current status of trial NCT00484510?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2007-04. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00484510?
The interventions under investigation include: placebo (DRUG), Ascorbic acid (Vitamin C) (DRUG).
Who is sponsoring clinical trial NCT00484510?
This trial is sponsored by Wayne State University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00484510's enrollment target sits among peer trials
110 632nd of 2000 higher than 1,361 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia